CD147/EMMPRIN: an effective therapeutic target for hepatocellular carcinoma

References

• Barrett T, Edgar R. (2006). Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Meth Enzymol, 411, 352–369.
   PubMed Web of Science ®Google Scholar
• Belton RJ Jr, Chen L, Mesquita FS, Nowak RA. (2008). Basigin-2 is a cell surface receptor for soluble basigin ligand. J Biol Chem, 283, 17805–17814.
   PubMed Web of Science ®Google Scholar
• Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. (1995). The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res, 55, 434–439.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35, 421–430.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208–1236.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang H, Gou X, Horikawa Y, Xing J, Chen Z. (2009). Upregulation of HAb18G/CD147 in activated human umbilical vein endothelial cells enhances the angiogenesis. Cancer Lett, 278, 113–121.
   PubMed Web of Science ®Google Scholar
• Chen ZN, Yang Z, Mi L, Jiang JL, Guo XN. (1999). Analysis on the structure and function of hepatoma transfer-associated factor HAb18G. J Cell Mol, 15, 34.
   Google Scholar
• Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, Xing JL, Bian HJ, Jiang JL, Wang XH, Shang P, Qian AR, Zhang SH, Li L, Li Y, Feng Q, Yu XL, Feng Y, Yang XM, Tian R, Wu ZB, Leng N, Mo TS, Kuang AR, Tan TZ, Li YC, Liang DR, Lu WS, Miao J, Xu GH, Zhang ZH, Nan KJ, Han J, Liu QG, Zhang HX, Zhu P. (2006). Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys, 65, 435–444.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang H, Gou X, Horikawa Y, Xing J, Chen Z. (2009). Upregulation of HAb18G/CD147 in activated human umbilical vein endothelial cells enhances the angiogenesis. Cancer Lett, 278, 113–121.
   PubMed Web of Science ®Google Scholar
• Curtin KD, Meinertzhagen IA, Wyman RJ. (2005). Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J Cell Sci, 118, 2649–2660.
   PubMed Web of Science ®Google Scholar
• Dai JY, Dou KF, Wang CH, Zhao P, Lau WB, Tao L, Wu YM, Tang J, Jiang JL, Chen ZN. (2009). The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer, 9, 337.
   Google Scholar
• Dai L, Bratoeva M, Toole BP, Qin Z, Parsons C. (2011). KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction. Int J Cancer. DOI: 10.1002/ijc.26428.
   Web of Science ®Google Scholar
• DeCastro R, Zhang Y, Guo H, Kataoka H, Gordon MK, Toole B, Biswas G. (1996). Human keratinocytes express EMMPRIN, an extracellular matrix metalloproteinase inducer. J Invest Dermatol, 106, 1260–1265.
   PubMed Web of Science ®Google Scholar
• Fossum S, Mallett S, Barclay AN. (1991). The MRC OX-47 antigen is a member of the immunoglobulin superfamily with an unusual transmembrane sequence. Eur J Immunol, 21, 671–679.
   PubMed Web of Science ®Google Scholar
• Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. (2005). EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie, 87, 361–368.
   PubMed Web of Science ®Google Scholar
• Gou X, Ru Q, Zhang H, Chen Y, Li L, Yang H, Xing J, Chen Z. (2009). HAb18G/CD147 inhibits starvation-induced autophagy in human hepatoma cell SMMC7721 with an involvement of Beclin 1 down-regulation. Cancer Sci, 100, 837–843.
   PubMed Web of Science ®Google Scholar
• Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. (1997). Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem, 272, 24–27.
   PubMed Web of Science ®Google Scholar
• Hou Q, Tang X, Liu H, Tang J, Yang Y, Jing X, Xiao Q, Wang W, Gou X, Wang Z. (2011). Berberine induces cell death in human hepatoma cells in vitro by downregulating CD147. Cancer Sci, 102, 1287–1292.
   Google Scholar
• Huang Y, Jiang J, Dou K, Chen Z. (2005). HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Eur J Cell Biol, 84, 59–73.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lu MQ, Li H, Xu C, Yi SH, Chen GH. (2006). Occurrence of cGMP/nitric oxide-sensitive store-operated calcium entry in fibroblasts and its effect on matrix metalloproteinase secretion. World J Gastroenterol, 12, 5483–5489.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. (2011). Global cancer statistics. CA Cancer J Clin, 61, 69–90.
   PubMed Web of Science ®Google Scholar
• Jia L, Wang S, Zhou H, Cao J, Hu Y, Zhang J. (2006). Caveolin-1 up-regulates CD147 glycosylation and the invasive capability of murine hepatocarcinoma cell lines. Int J Biochem Cell Biol, 38, 1584–1593.
   PubMed Web of Science ®Google Scholar
• Jia L, Cao J, Wei W, Wang S, Zuo Y, Zhang J. (2007). CD147 depletion down-regulates matrix metalloproteinase-11, vascular endothelial growth factor-A expression and the lymphatic metastasis potential of murine hepatocarcinoma Hca-F cells. Int J Biochem Cell Biol, 39, 2135–2142.
   PubMed Web of Science ®Google Scholar
• Jia L, Wang H, Qu S, Miao X, Zhang J. (2008a). CD147 regulates vascular endothelial growth factor-A expression, tumorigenicity, and chemosensitivity to curcumin in hepatocellular carcinoma. IUBMB Life, 60, 57–63.
   PubMed Web of Science ®Google Scholar
• Jia L, Xu H, Zhao Y, Jiang L, Yu J, Zhang J. (2008b). Expression of CD147 mediates tumor cells invasion and multidrug resistance in hepatocellular carcinoma. Cancer Invest, 26, 977–983.
   PubMed Web of Science ®Google Scholar
• Jiang JL, Chan HC, Zhou Q, Yu MK, Yao XY, Lam SY, Zhu H, Ho LS, Leung KM, Chen ZN. (2004). HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. Cell Mol Life Sci, 61, 2083–2091.
   PubMed Web of Science ®Google Scholar
• Kasinrerk W, Fiebiger E, Stefanová I, Baumruker T, Knapp W, Stockinger H. (1992). Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. J Immunol, 149, 847–854.
   PubMed Web of Science ®Google Scholar
• Kong LM, Liao CG, Chen L, Yang HS, Zhang SH, Zhang Z, Bian HJ, Xing JL, Chen ZN. (2011). Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma. J Cell Mol Med, 15, 1415–1428.
   PubMed Web of Science ®Google Scholar
• Ku XM, Liao CG, Li Y, Yang XM, Yang B, Yao XY, Wang L, Kong LM, Zhao P, Chen ZN. (2007). Epitope mapping of series of monoclonal antibodies against the hepatocellular carcinoma-associated antigen HAb18G/CD147. Scand J Immunol, 65, 435–443.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu J, Chen L, Chen L, Zhong WD, Zhang Z, Mi L, Zhang Y, Liao CG, Bian HJ, Jiang JL, Yang XM, Li XY, Fan CM, Zhu P, Fu L, Chen ZN. (2009). HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology, 54, 677–687.
   PubMed Web of Science ®Google Scholar
• Liao CG, Kong LM, Song F, Xing JL, Wang LX, Sun ZJ, Tang H, Yao H, Zhang Y, Wang L, Wang Y, Yang XM, Li Y, Chen ZN. (2011). Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion. Mol Cell Biol, 31, 2591–2604.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. (2003). Hepatocellular carcinoma. Lancet, 362, 1907–1917.
   PubMed Web of Science ®Google Scholar
• Lou CY, Feng YM, Qian AR, Li Y, Tang H, Shang P, Chen ZN. (2004). Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol, 10, 1462–1465.
   PubMed Web of Science ®Google Scholar
• MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. (2001). Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity, 15, 825–835.
   PubMed Web of Science ®Google Scholar
• Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, Li Y. (2008). The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother, 57, 1367–1379.
   PubMed Web of Science ®Google Scholar
• Muraoka K, Nabeshima K, Murayama T, Biswas C, Koono M. (1993). Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers. Int J Cancer, 55, 19–26.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74–108.
   PubMed Web of Science ®Google Scholar
• Polette M, Gilles C, Marchand V, Lorenzato M, Toole B, Tournier JM, Zucker S, Birembaut P. (1997). Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J Histochem Cytochem, 45, 703–709.
   PubMed Web of Science ®Google Scholar
• Qian AR, Zhang W, Cao JP, Yang PF, Gao X, Wang Z, Xu HY, Weng YY, Shang P. (2008). Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells. J Exp Clin Cancer Res, 27, 50.
   PubMed Web of Science ®Google Scholar
• Qin Z, Dai L, Slomiany MG, Toole BP, Parsons C. (2010). Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus. Cancer Res, 70, 3884–3889.
   PubMed Web of Science ®Google Scholar
• Rescher U, Ludwig C, Konietzko V, Kharitonenkov A, Gerke V. (2008). Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin rearrangement and cell adhesion. J Cell Sci, 121, 2177–2185.
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K. (2006). High incidence of EMMPRIN expression in human tumors. Int J Cancer, 119, 1800–1810.
   PubMed Web of Science ®Google Scholar
• Roberts LR, Gores GJ. (2006). Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs, 11, 469–487.
   PubMedGoogle Scholar
• Schlegel J, Redzic JS, Porter CC, Yurchenko V, Bukrinsky M, Labeikovsky W, Armstrong GS, Zhang F, Isern NG, Degregori J, Hodges R, Eisenmesser EZ. (2009). Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol, 391, 518–535.
   PubMed Web of Science ®Google Scholar
• Seong J. (2009). Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J, 50, 601–612.
   PubMed Web of Science ®Google Scholar
• Seulberger H, Lottspeich F, Risau W. (1990). The inducible blood–brain barrier specific molecule HT7 is a novel immunoglobulin-like cell surface glycoprotein. EMBO J, 9, 2151–2158.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. (2004). The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene, 23, 956–963.
   PubMed Web of Science ®Google Scholar
• Sun J, Hemler ME. (2001). Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res, 61, 2276–2281.
   PubMed Web of Science ®Google Scholar
• Tang W, Hemler ME. (2004). Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering. J Biol Chem, 279, 11112–11118.
   PubMed Web of Science ®Google Scholar
• Tang W, Chang SB, Hemler ME. (2004a). Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell, 15, 4043–4050.
   PubMed Web of Science ®Google Scholar
• Tang Y, Kesavan P, Nakada MT, Yan L. (2004b). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res, 2, 73–80.
   PubMed Web of Science ®Google Scholar
• Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, Chen ZN. (2008). Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2+ pathways. Cell Mol Life Sci, 65, 2933–2942.
   Google Scholar
• Toole BP. (2003). Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol, 54, 371–389.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS. (2006). Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology, 49, 388–395.
   PubMed Web of Science ®Google Scholar
• van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. (1997). Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol, 151, 665–670.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Llovet JM. (2011). Targeted therapies for hepatocellular carcinoma. Gastroenterology, 140, 1410–1426.
   PubMed Web of Science ®Google Scholar
• Wei J, Yang X, Zheng M, Wang M, Dai Y, Chen Z, Li N. (2011). The recombinant chimeric antibody chHAb18 against hepatocellular carcinoma can be produced in milk of transgenic mice. Transgenic Res, 20, 321–330.
   PubMed Web of Science ®Google Scholar
• Wu L, Yang YF, Ge NJ, Shen SQ, Liang J, Wang Y, Zhou WP, Shen F, Wu MC. (2010). Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients. Cancer Biother Radiopharm, 25, 657–663.
   PubMed Web of Science ®Google Scholar
• Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, Huang XF, Chen ZN, Bian H. (2011). HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-ß signaling and is transcriptionally regulated by Slug. Oncogene, 30, 4410–4427.
   PubMed Web of Science ®Google Scholar
• Wysocki PJ. (2010). Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs, 19, 265–274.
   PubMed Web of Science ®Google Scholar
• Xu HY, Qian AR, Shang P, Xu J, Kong LM, Bian HJ, Chen ZN. (2007a). siRNA targeted against HAb18G/CD147 inhibits MMP-2 secretion, actin and FAK expression in hepatocellular carcinoma cell line via ERK1/2 pathway. Cancer Lett, 247, 336–344.
   PubMed Web of Science ®Google Scholar
• Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN. (2007b). A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology, 45, 269–276.
   PubMed Web of Science ®Google Scholar
• Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN. (2007c). HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res, 5, 605–614.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Shibata M, Yamamoto S, Hagihara M, Asai N, Takahashi M, Mizutani S, Muramatsu T, Kadomatsu K. (2000). Homo-oligomer formation by basigin, an immunoglobulin superfamily member, via its N-terminal immunoglobulin domain. Eur J Biochem, 267, 4372–4380.
   PubMedGoogle Scholar
• Yu XL, Jiang JL, Li L, Feng Q, Xu J, Chen ZN. (2006). The glycosylation characteristic of hepatoma-associated antigen HAb18G/CD147 in human hepatoma cells. Int J Biochem Cell Biol, 38, 1939–1945.
   PubMed Web of Science ®Google Scholar
• Yu XL, Hu T, Du JM, Ding JP, Yang XM, Zhang J, Yang B, Shen X, Zhang Z, Zhong WD, Wen N, Jiang H, Zhu P, Chen ZN. (2008). Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem, 283, 18056–18065.
   PubMed Web of Science ®Google Scholar
• Yurchenko V, O’Connor M, Dai WW, Guo H, Toole B, Sherry B, Bukrinsky M. (2001). CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun, 288, 786–788.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen Z. (2006). CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther, 5, 808–814.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, Chen GS, Li Q, Qian F, Tian R, Wen N, Chen ZN. (2007). Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev, 16, 196–202.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang W, Tang J, Ma XK, Dai JY, Li Y, Jiang JL, Zhang SH, Chen ZN. (2010). Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci, 101, 387–395.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang W, Wang SJ, Yu XL, Tang J, Huang W, Li Y, Cui HY, Guo YS, Tavernier J, Zhang SH, Jiang JL, Chen ZN. (2011). HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology, 54, 2012–2024.
   Google Scholar
• Zhu H, Yang B, Yang X, Wang L, Xu J, Liao C, Feng Q, Tang H, Hu L, Chen Z, Li Y. (2009). A novel antibody fragment targeting HAb18G/CD147 with cytotoxicity and decreased immunogenicity. Cancer Biol Ther, 8, 1035–1044.
   PubMed Web of Science ®Google Scholar